Valuation: Senseonics Holdings, Inc.

Capitalization 281M 241M 219M 210M 384M 25.88B 397M 2.57B 1.03B 12.34B 1.05B 1.03B 44.07B P/E ratio 2026 *
-2.43x
P/E ratio 2027 * -2.95x
Enterprise value 281M 241M 219M 210M 384M 25.88B 397M 2.57B 1.03B 12.34B 1.05B 1.03B 44.07B EV / Sales 2026 *
4.67x
EV / Sales 2027 * 2.93x
Free-Float
93.84%
Yield 2026 *
-
Yield 2027 * -
1 day+0.66%
1 week-17.33%
Current month-16.93%
1 month-4.98%
3 months+2.08%
6 months-23.33%
Current year+24.46%
1 week 6.31
Extreme 6.31
8.45
1 month 6.31
Extreme 6.31
8.75
Current year 5.46
Extreme 5.46
8.75
1 year 5.25
Extreme 5.25
15.74
3 years 5
Extreme 5
28
5 years 5
Extreme 5
91.6
10 years 5
Extreme 5
111.2
Manager TitleAgeSince
Chief Executive Officer 64 30/11/2015
Director of Finance/CFO - 31/08/2022
Chief Tech/Sci/R&D Officer 75 05/03/2019
Director TitleAgeSince
Chairman 65 30/11/2015
Director/Board Member 67 30/11/2015
Director/Board Member 72 30/11/2015
Change 5d. change 1-year change 3-years change Capi.($)
+0.66%-17.33%-51.07%-67.29% 281M
-0.45%-1.45%-17.79%+8.28% 197B
-1.15%-1.09%+2.76%+14.61% 123B
-0.87%+1.42%+45.37%+135.79% 71.62B
+2.64%-3.65%+58.40%+99.57% 58.8B
-1.56%-5.23%-23.53%-27.71% 48.83B
-3.40%-11.00% - - 34.8B
-0.25%-0.36%-11.55%-40.69% 28.06B
-0.12%-3.40%+7.64%+27.97% 23.84B
-2.27%-4.11%-7.92%-24.14% 18.73B
Average -0.50%-4.59%+0.26%+14.04% 60.42B
Weighted average by Cap. -0.19%-2.31%+3.64%+29.33%

Financials

2026 *2027 *
Net sales 60.1M 51.68M 46.9M 44.98M 82.13M 5.54B 85.09M 551M 221M 2.64B 226M 221M 9.44B 95.72M 82.31M 74.69M 71.63M 131M 8.82B 136M 877M 351M 4.21B 359M 352M 15.03B
Net income -126M -108M -97.94M -93.93M -172M -11.57B -178M -1.15B -461M -5.52B -471M -461M -19.71B -119M -102M -93.01M -89.2M -163M -10.99B -169M -1.09B -437M -5.24B -447M -438M -18.72B
Net Debt - -
Logo Senseonics Holdings, Inc.
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.
Employees
117
Date Price Change Volume
04/03/26 6.870 $ +0.66% 819,447
03/03/26 6.825 $ -18.07% 1,338,387
02/03/26 8.330 $ +0.73% 489,501
27/02/26 8.270 $ -0.96% 538,589
26/02/26 8.350 $ +0.48% 283,565
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
6.870USD
Average target price
18.92USD
Spread / Average Target
+175.35%

Quarterly revenue - Rate of surprise